Trials
Search / Trial NCT06420609

Efficacy of a Proactive Approach to Death Thoughts in People With Advanced Cancer

Launched by UNIVERSITAT INTERNACIONAL DE CATALUNYA · May 14, 2024

Trial Information

Current as of February 14, 2025

Not yet recruiting

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • The inclusion criteria will be:
  • 1. patients with advanced cancer defined according to ASCO (American Society of Clinical Oncology) criteria referred for the initial palliative care (PC) consultation.
  • 2. age over 18 years
  • 3. ECOG 0-3 (functionality status)
  • 4. outpatients and inpatients
  • 5. patients who can sign the informed consent
  • 6. patients with the ability to maintain a conversation
  • The exclusion criteria will be:
  • 1. patients with acute symptoms that may affect their consciousness.
  • 2. patients with any uncontrolled symptoms that prevent collaboration in the study assessed according to clinical judgment
  • 3. moderate or severe cognitive impairment assessed according to clinical judgment
  • 4. patients included in another incompatible clinical trial

About Universitat Internacional De Catalunya

The Universitat Internacional de Catalunya (UIC) is a prestigious higher education institution situated in Barcelona, Spain, renowned for its commitment to academic excellence and innovation in research. With a strong emphasis on interdisciplinary collaboration, UIC actively engages in clinical trials that aim to advance medical knowledge and improve patient outcomes. The university's dedicated research teams are equipped with cutting-edge facilities and experienced professionals, enabling them to conduct rigorous studies across various health-related fields. UIC's focus on ethical practices and compliance ensures that all clinical trials are conducted with the highest standards of scientific integrity and participant safety.

Locations

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0